Trials Sponsors Conditions Drugs Pricing

Conditions

Bone Angioma

Keywords

percutaneous sclerosisethanol gelaggressive bone angioma

Outcome Measures

Primary Outcomes (1)

Number of complications identified in data collection
Number of complications identified in data collection
Day 1

Secondary Outcomes (1)

Number of lesion identified in data collection
Day 1

Study Arms (1)

Study population

Patients who have undergone percutaneous gel ethanol sclerosis for aggressive bone angioma at Saint-Etienne University Hospital.

Other: Collecting data from medical records

Interventions

Collecting data from medical recordsOther

Data collected: clinical data (particularly pain), biological data, imaging.

Study population

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

All patients who underwent percutaneous gel ethanol sclerosis for aggressive bone angioma at Saint-Étienne University Hospital will be included.

You may qualify if:

Every patients treated by gelled alcohol sclerotherapy for aggressive angiomas, in the University Hospital of Saint-Etienne.

Sponsors & Collaborators

Centre Hospitalier Universitaire de Saint Etienne
Otherlead

Study Sites (1)

CHU de Saint-Etienne

Saint-Priest-en-Jarez, 42270, France

RECRUITING

Sylvain Grange, MDCONTACT(0)477829066 ext. +33 grangesylvain@hotmail.fr

Sylvain Grange, MDPRINCIPAL INVESTIGATOR

Study Officials

Sylvain GRANGE, MD
Centre Hospitalier Universitaire de Saint Etienne
PRINCIPAL INVESTIGATOR

Central Study Contacts

Sylvain GRANGE, MD

CONTACT

(0)477829066 sylvain.grange@chu-st-étienne.fr

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 26, 2024

First Posted

September 23, 2024

Study Start

June 25, 2024

Actual (reported)

Primary Completion

December 2024

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Study population

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Study population

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations